Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →ML Fraud Detection Score: 97%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,817
Total Claims
$803K
Drug Cost
516
Beneficiaries
$1,557
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+69%
Opioid rate vs peers
3.8% vs 2.2% avg
+10%
Cost per patient vs peers
$1,557 vs $1,411 avg
+11%
Brand preference vs peers
11.8% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Our machine learning model — trained on 281 confirmed fraud cases — gives this provider a "Very High" fraud-pattern score. All 20 decision trees in our ensemble model agree that this provider's prescribing patterns resemble those of confirmed fraud cases. This is a statistical finding, not an accusation.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
3.8%
Opioid Rate
334
Opioid Claims
$8,354
Opioid Cost
12.9%
Long-Acting Rate
Brand vs Generic
Brand: 1,033 claims · $634K
Generic: 7,735 claims · $166K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 138 | $97K |
| Deutetrabenazine | 34 | $81K |
| Semaglutide | 52 | $60K |
| Sitagliptin Phosphate | 42 | $45K |
| Dulaglutide | 74 | $40K |
| Empagliflozin | 40 | $37K |
| Rivaroxaban | 34 | $33K |
| Mirabegron | 47 | $18K |
| Tirzepatide | 13 | $15K |
| Fluticasone/Vilanterol | 23 | $12K |
| Insulin Aspart | 27 | $11K |
| Insulin Glargine/Lixisenatide | 12 | $11K |
| Linagliptin | 16 | $8,379 |
| Insulin Glargine,hum.Rec.Anlog | 12 | $8,251 |
| Atorvastatin Calcium | 456 | $7,073 |
Prescribing Profile
Patient Profile
74
Avg Age
55%
Female
1.33
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data